Updates – Macro Trend

Trump Covid vaccine chief Slaoui says everyone in U.S. could be immunized by June

The entire U.S. population could be vaccinated against Covid-19 by June, and there could be enough doses to immunize the rest of the nearly 8 billion people in the world by early to mid-2022, the Trump administration’s vaccine chief said Tuesday. “Hopefully by the middle of the year, I hope most Americans will have been immunized, which […]

Read More

Asia stocks rise as private survey shows China’s factory activity growth hit 10-year high

Shares in Asia-Pacific were higher on Tuesday as investors reacted to the release of a private survey of China’s manufacturing activity. The Caixin/Markit manufacturing Purchasing Managers’ Index for November came in at 54.9 — its highest reading in a decade. PMI readings above 50 signify expansion, while those below that level represent contraction. On Monday, the […]

Read More

U.S. core capital goods orders beat expectations in October

New orders for key U.S.-made capital goods increased more than expected in October, but momentum is slowing in line with expectations for slower economic growth in the fourth quarter.

Read More

Retail trade group forecasts holiday sales rising 3.6% to 5.2%, ‘strong finish’ to 2020 in spite of pandemic

Retailers could end up having a strong finish to 2020, despite all of the challenges that the coronavirus pandemic has dealt the industry, according to a new forecast. The National Retail Federation said Monday it expects holiday sales during November and December to rise between 3.6% and 5.2% year over year, amounting to between $755.3 […]

Read More

Oxford-AstraZeneca Covid vaccine shows an average 70% effectiveness in preventing the virus

British pharmaceutical giant AstraZeneca said Monday an interim analysis of clinical trials showed its coronavirus vaccine has an average efficacy of 70% in protecting against the virus. It comes after a string of encouraging vaccine results in recent weeks, following late-stage trial readouts from Pfizer–BioNTech and Moderna. Pfizer and Moderna reported preliminary results showing that their respective Covid vaccines were around […]

Read More

October existing home sales see ‘spectacular’ 26.6% annual gain even with short supply and surging prices

Sales of existing homes in October soared well past expectations, rising 4.3% compared with September and 26.6% annually to a seasonally adjusted annualized rate of 6.85 million units, according to the National Association of Realtors. The NAR’s chief economist, Lawrence Yun, called the annual increase “a spectacular gain.” The annualized sales rate is the highest […]

Read More

Homebuilder confidence in November shatters record high, as buyers keep fleeing for the suburbs

The nation’s homebuilders have never been this happy. In November, builder confidence in the construction market for single-family homes soared to its third record high in as many months. Overall builder sentiment hit 90 on the monthly National Association of Home Builders’ Wells Fargo Housing Market Index. Anything above 50 is considered positive. Last November, […]

Read More

Why Moderna’s Vaccine Win Is a Giant Leap Against Pandemics

By Max Nisen (Bloomberg Opinion) — The world now seems likely to have at least two effective vaccines against Covid-19 with Monday’s announcement of positive early data from Moderna Inc.’s 30,000-person clinical trial. The result comes a week after Pfizer Inc. and BioNTech SE revealed a protection rate of more than 90% protection against disease. Moderna slightly one-upped […]

Read More

We can stop COVID-19: Moderna vaccine success gives world more hope

(Reuters) – Moderna Inc’s experimental vaccine is 94.5% effective in preventing COVID-19 based on interim data from a late-stage trial, the company said on Monday, becoming the second U.S. drugmaker to report results that far exceed expectations. Together with Pfizer Inc’s vaccine, which is also more than 90% effective, and pending more safety data and […]

Read More

Here’s how Goldman Sachs sees the vaccine getting delivered to Americans next year

The approval of a Covid-19 vaccine by the end of the year should lead to much of the United States being vaccinated during the first half of 2021, according to Goldman Sachs. On Thursday, the firm’s economic research team laid out a timeline for mass immunization with a successful vaccine, which included many high-risk individuals […]

Read More